ArticleNeuroradiology2026
Hyperdense middle cerebral artery sign is a prognostic factor of favourable long-term outcomes of mechanical thrombectomy in acute ischaemic stroke.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hyperdense middle cerebral artery sign is not associated with functional outcome following mechanical thrombectomy.Neuroradiology · 2026Article
- Prediction of functional outcome after mechanical thrombectomy using radiomics and deep learning features derived from intra-thrombus and peri-thrombus regions.Frontiers in neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeHyperdense middle cerebral artery sign (HMCAS) is a phenomenon highly specific for acute ischaemic stroke (AIS) that can be found in brain non-contrast computed tomography (NCCT). Previous studies concerning its association with outcomes of patients undergoing mechanical thrombectomy (MT) are inconclusive. Our aim was to assess the relationship between HMCAS presence and long-term outcomes of AIS patients undergoing MT.
methodsThe study included anterior circulation AIS patients treated with MT in the University Hospital in [ANONYMIZED] from 2019 to 2021, in whom admission NCCT and one-year follow-up were available. The clinical, laboratory and imaging data, as well as following outcomes: the occurrence of successful recanalization [defined as modified treatment in cerebral infarction (mTICI) score 2b-3], haemorrhagic complications (ICH), 90-day and 365-day rates of mortality and good functional outcome [defined as modified Rankin Scale (mRS) score 0-2] were compared between groups of patients with and without HMCAS on initial NCCT. The association of HMCAS presence with the abovementioned outcomes was assessed using multivariate logistic regression analysis.
resultsAmong 359 MT-treated patients with anterior circulation AIS, HMCAS was found in 244 (67.97%). The presence of HMCAS was independently associated with good functional outcome at 365 days (OR 1.956, 95% CI = 1.152-3.317, p = 0.013) as well as lower 90-day and 365-day mortality (OR = 0.464, 95% CI = 0.2517-0.856; p = 0.014 and OR 0.543, 95% CI: 0.313-0.940, p = 0.029, respectively).
conclusionThe presence HMCAS on admission NCCT is associated with favourable long-term outcome in AIS patients undergoing MT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.